OncoMyx Therapeutics

About:

OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.

Twitter/X: oncomyx

Top Investors: B Capital, Korea Investment Partners, Lumira Ventures, Boehringer Ingelheim Venture Fund, Delos Capital

Description:

OncoMyx Therapeutics develops oncolytic immunotherapies called myxoma (MYXV) to assist in creating an immune response and treat cancer. Its myxoma virus (MYXV) platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach which can be carried systemically by human leukocytes where it can then infect tumor cells. The company was founded in 2018 and is headquartered in Phoenix, Arizona.

Total Funding Amount:

$50M

Headquarters Location:

Phoenix, Arizona, United States

Founded Date:

2018-01-01

Founders:

Michael Wood, Steve Potts

Number of Employees:

11-50

Last Funding Date:

2021-12-09

IPO Status:

Private

Industries: